Patients with MSI-H cancers, including gastrointestinal (GI) cancer, have experienced excellent effects from programmed cell death protein-1 (PD-1)-based immune checkpoint inhibitor (ICI) immunotherapy [5–7]. This evidence concerns the gene PDCD1 and cancer.